Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease... (chief scientific officer of Sequoia. To...)

HOME >> MEDICINE >> TECHNOLOGY

Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor

Date:10/26/2008

chief scientific officer of Sequoia. "To address this need, we designed our protease inhibitor using a structure-based approach that targets highly conserved regions of the protease enzyme while minimizing interactions with regions of the enzyme that are highly malleable and thus susceptible to mutations."

First-in-human data with SPI-256

The primary objective of this Phase 1; randomized, double-blind, placebo-controlled, single- and escalating-dose crossover study was to evaluate the safety, tolerability and pharmacokinetics of single, ascending doses of SPI-256 administered alone or in combination with 100mg ritonavir (RTV) in healthy volunteers.

Data were presented on 59 healthy volunteers who took a single dose of SPI-256 (150mg, 450mg, 600mg, 900mg, or 1200mg) alone in Phase 1 of the study (n=38); in Phase 2 of the study, 37 subjects took either a single dose of SPI-256 (150mg, 450mg, 900mg) in combination with 100mg of RTV or received a single dose of 1200mg of SPI-256 with a high-fat meal.

SPI-256 demonstrated that it was generally safe and well tolerated in this healthy volunteer population. Adverse events (AEs) were reported by approximately half of subjects, although most were judged to be unrelated or unlikely to be related to study drug. In Phase 1 of the study, three subjects reported a total of 8 AEs possibly related to study drug. In Phase 2 of the study, two subjects reported one AE each that was possibly or definitely related to study drug.

Peak exposure to SPI-256 given alone was dose proportional over the range of 150 to 1200mg. In addition, a single dose of SPI-256 achieved sufficient plasma concentration to suggest the potential of once- or twice-daily dosing regimens in treatment-naive or -experienced patients.

When combined with ritonavir, SPI-256 levels were markedly elevated. This finding suggests that SPI-256 may be amenable to boosting with Sequoia's own pharmacokinetic enhancer, SPI-452, which is
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate

Post Your Comments:

Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease...(chief scientific officer of Sequoia. To...),Health